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α2-adrenoceptors (AR) lower central sympathetic output and peripheral catecholamine
release, thereby protecting against sympathetic hyperactivity and hypertension. Nor-
epinephrine re-uptake–transporter effectively (NET) removes norepinephrine from the
synapse. Overflow to plasma will therefore not reflect release. Here we tested if inhibition
of re-uptake allowed presynaptic α2AR release control to be reflected as differences in nor-
epinephrine overflow in anesthetized hypertensive spontaneously hypertensive rats (SHR)
and normotensive rats (WKY). We also tested if α2AR modulated the experiment-induced
epinephrine secretion, and a phenylephrine-induced, α1-adrenergic vasoconstriction. Blood
pressure was recorded through a femoral artery catheter, and cardiac output by ascending
aorta flow. After pre-treatment with NET inhibitor (desipramine), and/or α2AR antagonist
(yohimbine, L-659,066) or agonist (clonidine, ST-91), we injected phenylephrine. Arterial
blood was sampled 15 min later. Plasma catecholamine concentrations were not influ-
enced by phenylephrine, and therefore reflected effects of pre-treatment. Desipramine and
α2AR antagonist separately had little effect on norepinephrine overflow. Combined, they
increased norepinephrine overflow, particularly in SHR. Clonidine, but not ST-91, reduced,
and pertussis toxin increased norepinephrine overflow in SHR and epinephrine secretion
in both strains. L-659,066+ clonidine (central α2AR-stimulation) normalized the high blood
pressure, heart rate, and vascular tension in SHR. α2AR antagonists reduced phenylephrine-
induced vasoconstriction equally inWKY and SHR. Conclusions: α2AAR inhibition increased
norepinephrine overflow only when re-uptake was blocked, and then with particular effi-
cacy in SHR, possibly due to their high sympathetic tone. α2AAR inhibited epinephrine
secretion, particularly in SHR. α2AAR supported α1AR-induced vasoconstriction equally in
the two strains. α2AR malfunctions were therefore not detected in SHR under this basal
condition.
Keywords: α2-adrenoceptors, norepinephrine re-uptake transporter, hypertension, sympathetic nervous system
activity, norepinephrine, epinephrine, catecholamine release, plasma catecholamine concentrations
INTRODUCTION
α2-adrenoceptors (AR) are divided into three subtypes, i.e., α2A-,
α2B-, and α2CAR. Through their ability to lower central sympa-
thetic output and peripheral release of catecholamines from both
sympathetic nerve terminals and the adrenal medulla, they play
a significant role in preventing sympathetic hyperactivity (Starke,
2001). Deficiencies have been detected in the function of both
central and peripheral α2AR in the spontaneously hypertensive
rat (SHR) (Yamada et al., 1989; Remie et al., 1992; Reja et al.,
2002; Zugck et al., 2003). Since deletion of the α2AAR–gene cre-
ated a hypertensive mouse with high plasma norepinephrine levels
(Makaritsis et al., 1999b), a failing α2AR control of catecholamine
release may contribute to the elevated sympathetic activity (Judy
et al., 1976) and high blood pressure (BP) in SHR. α2AR in vas-
cular smooth muscle cells (VSMC) promote vasoconstriction,
whereas endothelial α2AR stimulate nitric oxide synthesis and
vasodilatation (Shafaroudi et al., 2005). Also these functions have
been shown to be failing in SHR (Feres et al., 1998; Berg and
Jensen, 2011). In addition, α2AR are involved in diabetes type II
and behavior and cognitive disorders including attention-deficit
hyperactivity (AD/HD) disorder (Hunt et al., 1995; Crassous et al.,
2007; Fagerholm et al., 2011). Diabetes type II is comorbid with
hypertension in the metabolic syndrome, and SHR is the most
frequently used animal model for studying AD/HD (Arime et al.,
2011).
The concentration of catecholamines in plasma is often used
as an indication of adrenergic activity. Unlike that of adrenal
epinephrine release, norepinephrine over flow to plasma will be
influenced by re-uptake through the norepinephrine transporter
(NET). The purpose of the present study was therefore to test
if inhibition of re-uptake allowed differences in the plasma nor-
epinephrine concentration to reflect the influence of presynaptic
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release control, here that of the α2-adrenceptor. We also tested if
α2AR activity modulated adrenal epinephrine release and a pro-
voked α1-adrenergic vascular tension-response, and if these func-
tions differed in SHR and their normotensive controls (WKY).
The results will demonstrate that presynaptic α2AR release inhi-
bition was reflected as differences in the plasma norepinephrine
concentration only when re-uptake was blocked, and then release
inhibition was demonstrated to be far greater in SHR than in
WKY. α2AR inhibited adrenal epinephrine secretion, also with
greater efficacy in SHR, and stimulation of central α2AR lowered
the elevated sympathetic tone and BP in this strain only.
MATERIALS AND METHODS
Ethical approval of the experiments was given by The Norwe-
gian Animal Research Authority (NARA). All experiments were
performed in accordance with the National Institutes of Health
(NIH) Guide for the Care and Use of Laboratory Animals.
EXPERIMENTAL PROCEDURE
Male, 12–14-weeks-old WKY (Wistar Kyoto, n= 79, 273± 4 g
body weight) and SHR (Okamoto, SHR/NHsd strain, n= 81,
277± 3 g body weight) on 12/12 h light/dark cycles were allowed
conventional rat chow diet (0.7% NaCl) and water ad lib until the
time of the experiment. The rats were anesthetized with sodium
pentobarbital (70–75 mg/kg, i.p.). As previously described (Berg
et al., 2010), the rats were instrumented with a catheter in the
femoral artery to monitor systolic (SBP) and diastolic (DBP)
BP. Cardiac output (CO=minus coronary flow) and heart rate
(HR) were measured with a 2SB perivascular flow probe on the
ascending aorta and a T206 Ultrasonic Transit-Time Flowmeter
(Transonic Systems Inc., Ithaca, NY, USA), entering the tho-
racic cavity through the third intercostal space. Mean arterial
BP [MBP= (SBP+DBP)/3+DBP] and total peripheral vascular
resistance (TPVR=MBP/CO) were calculated. The thorax was
closed with a suture, but the rats remained on a positive-pressure
ventilator throughout the experiment, ventilated with air. Previous
measurements of blood gas parameters demonstrated adequate
ventilation in both strains (Berg, 2002, 2003). Body tempera-
ture was maintained at 37–38˚C by external heating, guided by
a thermo sensor inserted inguinally into the abdominal cavity.
After completion of the surgery, the arterial catheter was flushed
with 0.15 ml PBS (0.01 M Na-phosphate, 0.14 M NaCl, pH 7.4)
containing 500 IU heparin/ml. Drugs were dissolved in PBS, and,
unless otherwise indicated, administered as bolus injections (0.6–
1 ml/kg) through a catheter in the femoral vein, flushed with
0.1 ml PBS.
EXPERIMENTAL DESIGN
Rats were pre-treated with vehicle (PBS, −10 min), the
peripherally restricted, non-selective α2AR antagonist L-659,066
(4.4µmol/kg; Clineschmidt et al., 1988) or the non-selective,
centrally active (Quaglia et al., 2011) α2AR antagonist yohim-
bine (5µmol/kg, −10 min; Berg, 2003), alone or after prior
administration of the NET inhibitor desipramine hydrochloride
(44µmol/kg, i.p., −5 h; Miralles et al., 2002). Rats were also pre-
treated with the non-selective, centrally active α2AR agonist cloni-
dine (151 nmol/kg,−15 min), alone or after prior administration
of L-659,066 as above, or with the peripherally restrictedα2(non-A)-
selective agonist ST-91 (24 nmol/kg,−10 min; Takano et al., 1992).
Since inhibitory G-protein (Gi) represents a main signaling path-
way for allα2AR,additional rats were injected with the Gi-inhibitor
Bordetella pertussis toxin (PTX, 15µg/kg, i.p., −48 h; Berg et al.,
2009), and pre-treated with PBS during the experiment. After pre-
treatment, all rats were injected with phenylephrine (120 nmol/kg)
to provoke an α1AR-mediated increase in TPVR. This concentra-
tion of phenylephrine was previously tested to activate a 3–4 times,
but still sub-maximal, rise in TPVR. In addition, in a time-control
group, phenylephrine was substituted with PBS. Control plasma
was collected from anesthetized rats, which were not on respira-
tor and not subjected to any surgery other than femoral artery
catheterization.
MEASUREMENT OF PLASMA CATECHOLAMINES
Arterial blood (1.5 ml) was collected 15 min after the injec-
tion of phenylephrine into tubes containing 40µl 0.2 M glu-
tathione and 0.2 M EGTA (4˚C). Plasma was stored at −80˚C
until the catecholamine concentrations were determined using an
HPLC-electrochemical detection method (Jensen et al., 2005).
STATISTICAL ANALYSES
Results are presented as mean values± SE mean. Each group
comprised 6–8 rats. To include differences in baselines, the car-
diovascular responses were expressed in % of baseline. The data
were averaged every minutes throughout all experiments, every 5 s
during the acute response to ST-91 and every 7th heart beat at the
narrow TPVR-peak response to phenylephrine. Differences in the
cardiovascular baselines, the response to pre-treatment, the TPVR-
peak-response to phenylephrine and plasma catecholamine con-
centrations were evaluated by over-all tests (one-way ANOVA), fol-
lowed by one- and/or two-sample Student’s t -tests. The clonidine-
response curves were analyzed using Repeated Measures Analyses
of Variance and Covariance, first as over-all tests within each strain,
and subsequently for each group separately or between groups.
Significant responses and group differences were then located
using one- and two-sample Student’s t -tests, respectively, at spe-
cific times. In the presence of out-liers, the two-sample Student’s
t -tests were substituted with non-parametric Kruskal–Wallis tests.
At each step, testing proceeded only when the presence of sig-
nificant responses and differences between groups was indicated.
Bonferroni adjustment was performed for all tests, except for the
catecholamine data, where P≤ 0.05 was considered significant.
DRUGS
L-659,066 was a kind gift from Merck, Sharp, and Dohme Labs,
Rahway, NJ, USA. ST-91 was from TOCRIS bioscience, Bristol,
UK, and the remaining drugs from Sigma Chemical Co., St. Louis,
MO, USA.
RESULTS
THE PLASMA CONCENTRATIONS OF NOREPINEPHRINE AND
EPINEPHRINE (TABLE 1)
The concentration of norepinephrine in plasma collected at the
end of the experiment in time-controls injected with PBS+PBS,
did not differ from that in control plasma, collected from rats
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Table 1 |The plasma concentration of norepinephrine and epinephrine.
WKY SHR
Norepinephrine (nM) Epinephrine (nM) Norepinephrine (nM) Epinephrine (nM)
Control plasma (no surgery) 0.6±0.1 0.1±0.1 0.8±0.1 0.1±0.1
Time-control (PBS+PBS) 0.9±0.4 8.2±1.3† 1.2±0.3 11.4±2.4†
PBS+phenylephrine 0.3±0.1 4.3±0.8 2.0±0.3* 9.0±1.9*
Clonidine+phenylephrine 0.4±0.1 0.4±0.1‡ 0.5±0.1‡ 0.8±0.2‡
ST-91+phenylephrine 0.2±0.1 3.6±0.8 1.5±0.6 7.7±0.9
L-659,066+phenylephrine 0.6±0.1 7.3±1.2‡ 1.8±0.5* 22.4±5.5*‡
L-659,066+ clonidine+phenylephrine 0.8±0.1 11.6±4.9§ 0.9±0.1‡§|| 5.6±2.2§||
Yohimbine+phenylephrine 0.8±0.8 7.2±2.0 3.9±0.7*‡ 15.3±2.4*
Desipramine+PBS+phenylephrine 0.8±0.2 1.6±0.5‡ 1.7±0.6 4.2±1.6‡
Desipramine+L-659,066+phenylephrine 1.9±1.4 10.9±7.2 30.2±11.6*‡¶ 16.3±4.4¶
Desipramine+ yohimbine+phenylephrine 2.2±0.5‡¶ 2.5±1.5 17.6±5.0*‡¶ 11.6±2.8*¶
PTX+phenylephrine 4.0±1.7 49.2±14.3‡ 8.0±1.1‡ 50.5±11.5‡
Differences were detected as indicated between corresponding SHR and WKY groups (* after SHR values), between control plasma and plasma from the time-control
groups (†), between time-controls and the PBS+phenylephrine groups (significant differences not detected), between the PBS+phenylephrine controls and the cor-
responding experimental groups (‡), between groups pre-treated with L-659,066+ clonidine and clonidine (§) or L-659,066 alone (||), and between groups pre-treated
with desipramine+PBS and desipramine+ α2AR antagonist (L-659,066 or yohimbine) (¶). *, †, ‡, §, ||, ¶ P≤0.05.
subjected to no other surgery than femoral artery catheterization.
The concentration in the time-controls also did not differ from
that in rats given PBS+ phenylephrine. These results showed
that the experiment itself and phenylephrine did not influence
norepinephrine overflow to plasma.
The plasma concentration of norepinephrine in the
phenylephrine-treated SHR controls was higher than that in WKY,
and was reduced after pre-treatment with the centrally active,
non-selective α2AR agonist clonidine. This reduction was in part
eliminated by prior administration of the peripherally restricted,
non-selective antagonist L-659,066. The peripherally restricted,
α2(non-A)-selective agonist ST-91 did not influence norepineph-
rine overflow in either strain. α2AR antagonist (L-659,055 and
yohimbine) and desipramine separately had no significant effect
on the norepinephrine concentration, except for a minor increase
after yohimbine in SHR. However, when combined, norepineph-
rine overflow increased, with particular efficacy in SHR. The Gi-
inhibitor PTX increased norepinephrine overflow in SHR, whereas
the increase in WKY was not statistically significant.
The plasma concentration of epinephrine in the time-controls
was higher than that in control plasma collected from rats not
subjected to surgery, but was not different from that in the
phenylephrine-treated controls. The plasma concentration of epi-
nephrine in the phenylephrine-treated controls was higher in
SHR than in WKY, but was in both strains reduced after pre-
treatment with clonidine, and increased after L-659,066. The
effect of L-659,066 was greater in SHR than in WKY. The
reduction after clonidine was in both strains abolished by addi-
tional pre-treatment with L-659,066. The peripherally restricted
α2(non-A)-selective agonist ST-91 did not influence the concentra-
tion of epinephrine. The secretion of epinephrine was reduced
after desipramine in both strains, but α2AR antagonist still
increased epinephrine secretion in desipramine-treated SHR. PTX
greatly increased the plasma epinephrine concentration in both
strains.
THE CARDIOVASCULAR RESPONSE TO α2AR ANTAGONISTS AND
AGONISTS
Baselines MBP, HR, and TPVR were higher in SHR than in WKY,
whereas CO was less (Table 2). Clonidine-induced a transient
increase in MBP and TPVR (Figure 1). ∆TPVR was less in SHR
than in WKY. The peripherally restricted L-659,066 reduced this
TPVR-response in WKY and eliminated the response in SHR.
Clonidine subsequently reduced TPVR to below baseline in both
strains, and L-659,066 had no effect on this response in either
strain (Figure 1). The fall in tension following clonidine in the
presence of L-659,066 was greater in SHR than in WKY, although
TPVR remained higher in SHR (P< 0.001), but was not different
from that in the WKY controls (P=NS; Table 2). The clonidine-
induced reduction in TPVR was paralleled by hypotension in SHR
only (Figure 1), eliminating the difference in MBP between the two
strains (Table 2). Clonidine-induced an L-659,066-sensitive, tran-
sient bradycardia in WKY, but an L-659,066-insensitive, sustained
bradycardia in SHR (Figure 1). The central effect of clonidine in
SHR therefore eliminated the strain-related difference in baseline
MBP, TPVR, and HR (Table 2).
The peripheral, α2(non-A)-selective agonist ST-91 induced a
transient increase in MBP and TPVR, followed by a reduction
in CO, but had little effect on HR (not shown). After 10 min,
MBP, HR, CO and TPVR did not differ from that in the controls
(Table 2).
Baseline HR in both strains and MBP in SHR were lower after
yohimbine (Table 2). After desipramine, L-659,066 reduced HR
in WKY, but increased HR in SHR. Also yohimbine increased HR
and, in addition, MBP and TPVR in desipramine-treated SHR.
PTX lowered MBP in WKY only.
THE ROLE OF α2AR IN MODULATING AN α1AR-ACTIVATED
VASOCONSTRICTION
The α1AR-selective agonist phenylephrine-induced a sharp and
transient rise in TPVR (Figure 2) and MBP (∆MBP= 118± 9
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Table 2 | Cardiovascular baselines prior to phenylephrine and, in parenthesis, the response to pre-treatment during the acute experiment.
Pre-treatment WKY SHR
MBP
mm Hg
HR
beats/min
CO
ml/min
TPVR
mm Hg/ml/min
MBP
mm Hg
HR
beats/min
CO
ml/min
TPVR
mm Hg/ml/min
PBS 70±4
(−3±4)
328±5
(−12±8)
31±3
(2±2)
2.4±0.2
(−0.3±0.1)
91±6*
(−3±6)
392±11*
(−16±3)
19±1*
(−1±1)
4.8±0.5*
(0.0±0.2)
Clonidine 57±5
(−2±5)
310±6
(−26±7)
42±2
(14±1)†
1.4±0.1†
(−0.8±0.1)†
57±3†
(−33±7)*†
292±6†
(−127±17)*†
21±1*
(3±1)*
2.7±0.1*†
(−2.3±0.3)*†
ST-91 75±5
(−5±3)
338±7
(−20±6)
32±3
(2±1)
2.6±0.3
(−0.6±0.2)
104±9
(16±7)
364±11
(−36±7)
21±0
(1±0)
5.0±0.4
(0.6±0.3)
L-659,066 52±10
(−10±2)
321±14
(−6±10)
24±10
(1±1)
2.1±0.3
(−0.6±0.2)
79±9
(−7±7)
437±13*
(4±10)
21±3
(1±2)
4.2±0.6
(−0.4±0.2)
L-659,066+
clonidine
38±2†‡
(−26±8)†
303±6
(−23±11)§
34±4
(5±2)
1.2±0.1†
(−1.2±0.3)
43±4†§
(−55±7)†§
318±12†§
(−89±12)*†§
18±3*
(−3±2)*
2.5±0.2*†§
(−2.1±0.2)*†§
Yohimbine 54±5
(−12±2)
277±10†
(−38±5)
30±2
(1±0)
1.8±0.1
(−0.6±0.1)
56±4†
(−22±5)
327±7*†
(−42±14)
15±2*
(−3±2)
4.0±0.3*
(−0.7±0.4)
PBS after desipramine 51±5
(−4±2)
329±18
(−21±13)
29±3
(1±1)
1.8±0.3
(−0.2±0.1)
64±5
(−5±2)
347±10
(−24±10)
16±1*
(−0±1)
4.0±0.3*
(−0.2±0.1)
L-659,066 after
desipramine
41±5†
(−12±3)
314±25
(−40±0)†
21±4
(−1±2)
2.0±0.2
(−0.5±0.1)
88±9*
(9±12)
486±7† ||
(32±11)*†||
21±2
(1±1)
4.3±0.3*
(0.2±0.4)
Yohimbine after
desipramine
64±4
(0±1)
340±9
(−18±8)
36±3
(3±1)
1.8±0.1
(−0.1±0.0)
88±7*
(26±2)*†||
459±13*†||
(42±9)*†||
22±1*||
(3±1)||
4.0±0.2*
(0.8±0.1)*||
PBS after PTX 45±4†
(−4±2)
352±8
(−9±5)
37±7
(−1±3)
1.5±0.3
(0.1±0.2)
63±7
(−4±3)
429±10*
(−12±3)
26±5
(−2±3)
3.0±0.9
(0.0±0.2)
Comparisons were made between the WKY and SHR controls (*), between the PBS-controls and the experimental groups (†), between groups pre-treated with
L-659,066 + clonidine and clonidine (‡) or L-659066 alone (§), and between groups pre-treated with desipramine + PBS and desipramine + L-659,066/yohimbine (||).
*P = 0.0125; †P = 0.0056; ‡, §, ||P = 0.025.
and 120± 14% in WKY and SHR, respectively) with negligi-
ble changes in HR (∆HR=−7± 4%, P< 0.001, and −7± 1%,
P=NS, respectively). The TPVR-response to phenylephrine
was not different after pre-treatment with clonidine or ST-91,
but was reduced after L-659,066, L-659,066+ clonidine, yohim-
bine, the NET inhibitor desipramine, and the Gi-inhibitor PTX
(Figure 2). Additional pre-treatment with L-659,066 or yohimbine
in desipramine-treated rats, further reduced the TPVR-response to
phenylephrine, except in desipramine+ L-659,066-treated WKY.
Significant strain-related differences in the TPVR-response to
phenylephrine without or with pre-treatment were not detected.
DISCUSSION
The main finding in the present study was that peripheral α2AR
antagonist increased norepinephrine overflow to plasma only
when re-uptake was blocked, and then with a far greater efficacy
in SHR than in WKY. α2AR inhibition of adrenal epinephrine
release was also more pronounced in SHR. α2AAR appeared to
be the main subtype responsible for peripheral catecholamine
release inhibition. We also found that clonidine, through a cen-
tral action, normalized the high MBP, HR, and TPVR in SHR,
but strain-related differences in peripheral α2AR modulation of
α1AR-mediated vasoconstriction were not detected.
Although all rats received phenylephrine between pre-
treatment and the collection of blood, plasma catecholamine levels
in the phenylephrine-control groups did not differ from that in
time-controls injected with PBS instead of phenylephrine. From
this observation, we concluded that phenylephrine itself did not
influence the plasma catecholamine concentrations. Differences
in the concentration of circulating catecholamines were therefore
due to the treatment given prior to phenylephrine.
Norepinephrine is normally released from nerve terminal vesi-
cles by exocytosis and removed from the synapse by re-uptake
through NET. Vesicular release is Ca2+-dependent and under
presynaptic control, and inhibited by presynaptic α2AR (Starke,
2001). Due to the efficacy of these two mechanisms, norepineph-
rine escape from the synapse into blood was low. α2AR antagonist
or desipramine alone had no or only little effect on norepinephrine
overflow in either strain, indicating that inhibition of one mech-
anism was compensated by the other. However, α2AR antagonist
and desipramine combined increased the plasma norepinephrine
concentration, and with particular efficacy in SHR.
Unlike that observed for norepinephrine, the plasma concen-
tration of epinephrine in rats exposed to a full experiment was
higher than that in control rats, not exposed to artificial ventilation
or surgery other than arterial catheterization. This epinephrine
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FIGURE 1 |The changes in MBP,TPVR, and HR in response to the
centrally active, non-selective α2AR agonist clonidine, without or with
prior administration of the peripherally restricted, non-selective α2AR
antagonist L-659,066. After curve evaluations, significant responses
( within symbols) and group differences at peak response (*in brackets left
of curves) and at 15 min (*in brackets right of curves) were detected as
indicated. Cardiovascular baselines prior to clonidine are shown inTable 2.
,*P≤0.025.
secretion was therefore caused by the experiment itself, probably
due to surgical stress and activation of the sympatho-adrenal axis.
NET did not influence adrenal epinephrine overflow, since the epi-
nephrine concentration in plasma was not increased by tyramine
(Berg et al., 2010), which activates reverse transport through NET.
The elevated plasma norepinephrine concentration after α2AR
antagonist in desipramine-treated rats was therefore not paral-
leled by an increase in circulating epinephrine. In fact, desipramine
reduced the secretion of epinephrine in both strains, most likely
through its action on central pathways (Eisenhofer et al., 1991).
In agreement with that clonidine lowered central sympathetic
output and BP in conscious rats by stimulating central α2AAR
(MacMillan et al., 1996; Makaritsis et al., 1999a; Philipp et al.,
2002), clonidine in the presence of the peripherally restricted L-
659,066, i.e., through a central action, normalized the high MBP,
HR, and TPVR baselines in SHR. Clonidine in the presence of
L-659,066 also lowered norepinephrine overflow to plasma in SHR
only. The central sympathetic tone was therefore clearly elevated in
SHR, and could be lowered by clonidine. This observation showed
that a high sympathetic tone played an important role in sustain-
ing the hypertension in SHR, possibly due to an insufficient α2AR
control of central sympathetic output. However, the α2AR were
present and functional since they did respond to agonist.
Peripheral α2AR actively inhibited norepinephrine release in
SHR, demonstrated by the increase in overflow to plasma after
the peripheral antagonist L-659,066, and also yohimbine, when
re-uptake was blocked with desipramine. The overflow was by far
greater in SHR than in WKY. This observation may be explained
by the elevated sympathetic tone in this strain, resulting in a
higher peripheral, vesicular release, with subsequent, enhanced
auto-activation of the presynaptic, release-inhibiting α2AR. Rep-
resenting the last line of defense against sympathetic hyperactivity,
it is also possible that theα2AR were in fact up-regulated in SHR, in
order to prevent excessive release due to the elevated sympathetic
tone in this strain.
Peripherally restricted, subtype-selective α2AR agonists or
antagonists are not available. However, clonidine reduced nor-
epinephrine overflow in SHR, and the secretion of epinephrine in
both strains. The reduction in norepinephrine overflow was in part
reversed and that of epinephrine fully reversed by the peripher-
ally restricted antagonist L-659,066, demonstrating involvement
of peripheral α2AR. Similar reductions were not observed after
the peripheral, α2(non-A)-selective agonist ST-91. We therefore
deduced that the α2AAR was the main subtype responsible for
peripheral inhibition of norepinephrine and epinephrine release
in both WKY and SHR. This conclusion was compatible with
previous studies on genetically modified mice, whereα2AAR inhib-
ited release at high stimulation frequencies, whereas inhibition of
α2CAR hampered release at lower stimulation frequencies (Hein
et al., 1999). Since sympathetic output was clearly enhanced in
SHR, the basal sympathetic tone in this strain may resemble
the experimental higher frequencies. Furthermore, inhibition of
epinephrine release from the adrenal medulla involved the α2A-
subtype in rat and man (Lymperopoulos et al., 2007), although
the α2C-subtype in the mouse (Brede et al., 2003; Moura et al.,
2006). α2AAR catecholamine release inhibition apparently sig-
naled through Gi, since PTX increased the plasma concentration
of norepinephrine in SHR and greatly that of epinephrine in both
strains. The more prominent effect of PTX on the plasma concen-
tration of epinephrine compared to that of norepinephrine was
likely to be explained by norepinephrine re-uptake through NET.
Catecholamine-induced vasoconstriction is mediated not only
through the α1AR-phospholipase C pathway, but also by α2AR.
VSMC α2AR may signal through Gi, and, in that manner, oppose
the vasodilatory effect of the adenylyl cyclase – cyclic AMP path-
way, activated by VSMC βAR and stimulatory G-protein. A shift in
the VSMC α2AR – βAR balance may therefore explain why α2AR
antagonist and PTX reduced the phenylephrine-induced, α1AR-
mediated vasoconstriction. The VSMC α2AR tone appeared max-
imally stimulated, since it could not be further stimulated by cloni-
dine or ST-91. Unlike the effect of α2AR antagonist on norepineph-
rine overflow, α2AR antagonist modulated the TPVR-response to
phenylephrine also in the absence of NET inhibitor. This was
as expected, since activation of postsynaptic α2AR takes place
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FIGURE 2 |The influence of α2AR on theTPVR-peak-response to the α1AR agonist phenylephrine. The rats were pre-treated as indicated by symbol
legends. TPVR prior to phenylephrine is shown inTable 2. Within columns; significant responses. *In brackets; significant group differences. P≤0.005;
*P≤0.0042.
within the synapse as part of the physiological response, and
likely to be less sensitive to NET re-uptake than overflow to
plasma. Still, desipramine alone reduced the TPVR-response to
phenylephrine. This may be due to the central sympatholytic
action of desipramine, or an increased βAR vasodilatation fol-
lowing the increased concentration of norepinephrine within the
synapse when re-uptake was blocked. When the TPVR-response
to phenylephrine was expressed in integers of baseline, strain-
related differences in theα2AR modulation were not detected, even
though malfunctions have been reported for VSMC α2AR in SHR
(Feres et al., 1998). The smaller, initial clonidine-induced vaso-
constriction in SHR compared to WKY, was most likely explained
by an overlap from the subsequent reduced sympathetic tone due
to activation of central α2AR in this strain.
The present experiments were performed on pentobarbiturate-
anesthetized rats on a positive-pressure ventilator. Due to the
anesthesia, the large increase in MBP induced by phenylephrine
had hardly any effect on HR, similar to that previously observed
during an acute fall in MBP activated by bradykinin (Bjørnstad-
Østensen and Berg, 1994). The observed cardiovascular responses
were therefore without interference from baroreflex activation.
However, the positive-pressure ventilation hampered thoracic
venous return to the right atrium, and, hence, lowered stroke vol-
ume, CO, and BP, but had little effect on baseline TPVR. This
effect was more prominent in SHR than in WKY. However, this
influence did not differ between the groups within each strain,
and therefore was not likely to have an impact on the response
to the pharmacological interventions or on the conclusions made
there from.
The 5-HT1A-agonistic effect of yohimbine may through presy-
naptic intervention inhibit norepinephrine release (Moran et al.,
1998; Quaglia et al., 2011). This activity did not seem to play
a prominent role in its effect on release, since yohimbine alone
in SHR, and in the presence of desipramine in both strains,
increased norepinephrine overflow to plasma. Activation of a
central 5-HT1A-component may explain why yohimbine lowered
baseline HR (Villalon and Centurion, 2007). However, both α2AR
antagonists increased HR and to some extent also TPVR in
the desipramine-treated SHR. This increase was likely to result
from a high norepinephrine synaptic concentration in these two
groups.
CONCLUSION AND IMPLICATIONS
α2AR antagonist did not increase norepinephrine overflow to
plasma unless re-uptake through NET was blocked. Thus, unless
NET re-uptake was prevented, the norepinephrine concentration
in plasma was not a good indicator of sympathetic nerve activity,
and not suited for studying presynaptic norepinephrine release
control. The present experiments provided the conditions under
which the plasma concentrations will reflect differences in cate-
cholamine release so that mechanisms influencing release can be
studied in whole animal experiments.
α2AR malfunctions in the peripheral control of catecholamine
release or the support of α1AR-mediated vasoconstriction were
not detected in SHR. This may be different when the sympathetic
nervous system is activated, since the inhibitory effect of PTX on
vasoconstriction evoked by tyramine-stimulated norepinephrine
release was less in SHR than in WKY (Berg et al., 2009), whereas a
strain-related difference was not seen for the effect of PTX on the
present phenylephrine-induced vasoconstriction.
α2A appeared to be the main α2AR subtype responsible for
peripheral inhibition of norepinephrine in SHR and epinephrine
release in both strains, both signaling through PTX-sensitive Gi.
The high central sympathetic tone and cardiovascular baselines
in SHR were normalized by stimulation of central α2AR. This
elevated sympathetic tone may be the reason why the effect of
α2AR antagonist on catecholamine release was greater in SHR
than in WKY. The high norepinephrine concentration in plasma
after α2AR antagonist in the presence of NET inhibitor may be uti-
lized for diagnostic purposes to identify patients with hypertension
due to sympathetic hyperactivity. Also a clonidine-induced, sus-
tained bradycardia in the presence of peripherally restricted α2AR
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antagonist, appeared to be specifically related to the sympathetic
hyperactivity in SHR. Such diagnostics tools are needed in order to
select those patients who will benefit from newly developed ther-
apies targeting the autonomic imbalance in hypertension, such as
implanted barostimulator and renal nerve ablation.
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